H.R. 8205
Extends ALS research and treatment programs through 2031
Keeps federal grants and a shared agency partnership running through 2031 to develop and review treatments for ALS and other nerve-destroying diseases.
- Renews health agency grants for ALS drug research through 2031
- Funds study of treatments for people who cannot join clinical trials
- Grantees must quickly report serious, unexpected side effects
- The FDA must publish a five-year plan and a report on its actions
Passed the House · Senate's turn